Nurix Therapeutics presents data from GS-6791

Nurix Therapeutics (NRIX) announced the presentation of preclinical data from GS-6791/NX-0479, a novel IRAK4 protein degrader discovered as part of the company’s ongoing research collaboration with Gilead Sciences (GILD). The findings support advancement of GS-6791 into clinical studies and are being presented at the European Academy of Dermatology and Venereology, EADV, Congress, taking place September 17-20, 2025, in Paris, France. Preclinical data presented at EADV demonstrate that GS-6791 is a potent, selective, oral IRAK4 degrader with activity across immune and epithelial systems relevant to dermatologic disease: Potent IRAK4 degradation: Achieved near-complete knockdown in human blood and keratinocytes. Deep cytokine pathway inhibition: Potency against IL-1 and IL-36 signaling. Dermatology relevance: Reduced proinflammatory cytokines and disease-associated gene expression in keratinocytes and 3D reconstructed human epidermis. In vivo efficacy: Suppressed cytokines in an IL-1beta challenge model; reduced skin inflammation and improved barrier function in a mouse dermatitis model. Gilead exercised its option to license GS-6791 in March 2023, after which Gilead became responsible for all further development. The Investigational New Drug application for GS-6791 was cleared by the U.S. Food and Drug Administration in April 2025.